Hoth Therapeutics Inc Net Assets
Hoth Therapeutics Inc net assets. Based on the latest financial reports, Hoth Therapeutics Inc (HOTH) has net assets worth $8.20 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.58 Million) and total liabilities ($1.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore HOTH net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.20 Million |
| % of Total Assets | 85.56% |
| Annual Growth Rate | 22.86% |
| 5-Year Change | -37.76% |
| 10-Year Change | N/A |
| Growth Volatility | 477.59 |
Net Assets of Hoth Therapeutics Inc (2017–2025)
Net assets of Hoth Therapeutics Inc from 2017 to 2025. This chart illustrates how Hoth Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See HOTH net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Hoth Therapeutics Inc (2017–2025)
The table below shows the annual net assets of Hoth Therapeutics Inc from 2017 to 2025. For live market cap and overall valuation, see HOTH market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.15 Million | -10.58% |
| 2024-12-31 | $6.88 Million | -27.88% |
| 2023-12-31 | $9.54 Million | +86.23% |
| 2022-12-31 | $5.12 Million | -48.17% |
| 2021-12-31 | $9.88 Million | +112.72% |
| 2020-12-31 | $4.65 Million | +93.89% |
| 2019-12-31 | $2.40 Million | +1446.16% |
| 2018-12-31 | $154.97K | -86.92% |
| 2017-12-31 | $1.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hoth Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7086386200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Hoth Therapeutics Inc Net Assets Breakdown (December 2025)
Hoth Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.55K | 0.03% |
| Other Comprehensive Income | $10.83K | 0.18% |
| Other Components | $79.02 Million | 1284.68% |
| Total Equity | $6.15 Million | 100.00% |
Hoth Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Hoth Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NextTrip Inc
NASDAQ:NTRP
|
$15.67 Million |
|
VIRINCHI ORD (BSE)
NSE:VIRINCHI
|
$15.67 Million |
|
Immo Mcc NV
BR:MCC
|
$15.68 Million |
|
SenzaGen AB
ST:SENZA
|
$15.69 Million |
|
Barnwell Industries Inc
NYSE MKT:BRN
|
$15.66 Million |
|
Vincit Group Oyj
HE:VINCIT
|
$15.65 Million |
|
Lighting and Equipment Public Company Limited
BK:L&E
|
$15.64 Million |
|
Metavista3D Inc.
V:DDD
|
$15.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hoth Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,878,859 to 6,150,769, a change of -728,090 (-10.6%).
- Net loss of 12,469,302 reduced equity.
- New share issuances of 4,118,865 increased equity.
- Other comprehensive income increased equity by 1,768.
- Other factors increased equity by 7,620,579.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.47 Million | -202.73% |
| Share Issuances | $4.12 Million | +66.97% |
| Other Comprehensive Income | $1.77K | +0.03% |
| Other Changes | $7.62 Million | +123.9% |
| Total Change | $- | -10.58% |
Book Value vs Market Value Analysis
This analysis compares Hoth Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.27x to 1.84x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $3.08 | $0.82 | x |
| 2018-12-31 | $0.41 | $0.82 | x |
| 2019-12-31 | $6.54 | $0.82 | x |
| 2020-12-31 | $9.39 | $0.82 | x |
| 2021-12-31 | $11.06 | $0.82 | x |
| 2022-12-31 | $4.28 | $0.82 | x |
| 2023-12-31 | $2.80 | $0.82 | x |
| 2024-12-31 | $1.08 | $0.82 | x |
| 2025-12-31 | $0.45 | $0.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hoth Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -202.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-202.73%) is above the historical average (-336.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -170.16% | 0.00% | 0.00x | 1.04x | $-2.13 Million |
| 2018 | -1610.38% | 0.00% | 0.00x | 3.25x | $-2.51 Million |
| 2019 | -321.13% | 0.00% | 0.00x | 1.18x | $-7.93 Million |
| 2020 | -154.94% | 0.00% | 0.00x | 1.13x | $-7.66 Million |
| 2021 | -144.84% | 0.00% | 0.00x | 1.11x | $-15.30 Million |
| 2022 | -222.04% | 0.00% | 0.00x | 1.32x | $-11.88 Million |
| 2023 | -82.25% | 0.00% | 0.00x | 1.07x | $-8.80 Million |
| 2024 | -119.04% | 0.00% | 0.00x | 1.12x | $-8.88 Million |
| 2025 | -202.73% | 0.00% | 0.00x | 1.24x | $-13.08 Million |
Industry Comparison
This section compares Hoth Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hoth Therapeutics Inc (HOTH) | $8.20 Million | -170.16% | 0.17x | $15.67 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to … Read more